Cardiac Arrhythmias: New Therapeutic Drugs and Devices Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984
In summary, there are many animal models that are useful in selecting new antiarrhythmic drugs. The selection of which model is most idea depends upon precisely what question is being asked. The large number of experimental models used to evaluate antiarrhythmic compounds points out the inability of...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
New York, NY
Springer US
1985, 1985
|
| Edition: | 1st ed. 1985 |
| Series: | Developments in Cardiovascular Medicine
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 20 Study designs to evaluate atrial arrhythmias are easy
- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection
- 22 Approaches to drug selection and serial drug testing
- Panel Discussion: Evaluation of atrial arrhythmias
- Participants
- I Basic Considerations
- 1 What animal models are useful in selecting new antiarrhythmic drugs?
- 2 How to test for antiarrhythmic drugs
- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?
- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?
- Panel Discussion: Basic considerations
- II Status of Specific Antiarrhythmic Agents
- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — efficacy in the treatment of ventricular arrhythmias: current status and controversies
- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents
- 7 Class IC antiarrhythmic agents: status — 1984
- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias
- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol
- Panel Discussion: Status of specific antiarrhythmic agents
- III Special Considerations and FDA Standards
- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice
- 11 Use of a computer in the new drug evaluation process
- 12 Sudden cardiac death — failure or effect of antiarrhythmic drug therapy?
- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs
- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?
- Panel Discussion: Special considerations and FDA standards
- IV New Antiarrhythmic Devices
- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?
- 16 Pacing for ventricular tachycardia
- 17 Termination of ventricular tachycardia by transvenous cardioversion
- 18 The automatic implantable cardioverter/defibrillator
- 19 New antiarrhythmia devices — FDA’srequirements for effectiveness
- Panel Discussion: New antiarrhythmic devices
- V Evaluation Of Atrial Arrhythmias